0
0
New Delhi, May 12:
A new cholesterol-lowering medication, Obicetrapib, could soon offer hope to millions at high risk of heart attack and stroke, according to results from a major international clinical trial led by Monash University’s Victorian Heart Institute in Australia.
Obicetrapib, a once-daily oral pill, was tested in the phase 3 BROADWAY trial involving more than 2,500 participants with established cardiovascular disease or inherited high cholesterol. The study found that, when added to standard cholesterol-lowering medications, Obicetrapib significantly reduced both LDL cholesterol-commonly known as “bad cholesterol”-and lipoprotein(a), or Lp(a), a genetic risk factor that has long eluded effective treatment.
Significant Reductions in Key Risk Factors
Over a 12-week period, patients taking Obicetrapib saw average reductions of 32.6% in LDL cholesterol and 33.5% in Lp(a), compared to those on placebo. Many participants achieved guideline-recommended cholesterol targets for the first time, an outcome researchers hailed as a critical advance for those who have not responded to existing therapies.
Professor Stephen Nicholls, who led the study, emphasized the drug’s dual impact:
“Obicetrapib offers a promising new option-not only did it lower LDL cholesterol by over 30%, but we also saw a reduction in Lp(a), which is much harder to treat and has been linked to increased heart disease risk”.
Safety and Tolerability
The BROADWAY trial reported that Obicetrapib was well tolerated, with a safety profile similar to placebo and consistent with earlier studies. Rates of adverse events were nearly identical between the Obicetrapib and placebo groups, with no significant differences in severity or reasons for discontinuation.
Addressing an Unmet Need
LDL cholesterol is a well-established cause of arterial plaque buildup, increasing the risk of heart attack and stroke. Lp(a), meanwhile, is a genetically inherited risk factor that accelerates artery damage and has, until now, lacked effective therapies. The ability of Obicetrapib to target both these risk factors could represent a major advance in cardiovascular disease prevention, especially for patients who have struggled to control their cholesterol with available treatments.
Professor Nicholls noted,
“This is a potential game-changer for people whose cholesterol remains high despite existing therapies. It’s simple, effective, and addresses risks we’ve struggled to treat”.
What’s Next?
While the results are promising, researchers caution that longer-term studies are needed to determine whether these improvements in cholesterol translate into fewer heart attacks and strokes. Ongoing trials, including the PREVAIL study, are expected to provide further evidence on the drug’s impact on cardiovascular outcomes in the coming years.
Disclaimer:
Obicetrapib is currently an investigational medication and has not yet received regulatory approval for general use. The findings reported here are based on interim clinical trial results. Patients should not make any changes to their medication regimen without consulting a healthcare professional. Further studies are ongoing to confirm the long-term safety and effectiveness of Obicetrapib in reducing cardiovascular events.
Citations:
